Compare Amphastar Pharmaceuticals Inc (AMPH) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Virgin Galactic (SPCE) trades at $2.57, down 1.91% on the day, with a bearish technical signal from moving averages. The company continues to report significant losses with negative gross profit margins of -6,127.71% and net income margin of -19,781.3% for 2025. Recent news highlights volatility in space stocks following SpaceX's IPO, with SPCE experiencing sharp price swings. Cash flow remains negative at -$35.17 million for 2025, though showing improvement from previous years.

The outlook remains challenging with persistent operational losses and high cash burn. Investment opportunity exists if the company can achieve commercial scale and profitability, but risks include execution challenges, competitive pressure, and dependence on additional financing. Analyst consensus is divided with 29% buy, 41% hold, and 29% sell ratings, reflecting uncertainty about the company's path to profitability.